Lung cancer is the leading cause of cancer death among both men and women, accounting for more than 28% of all cancer deaths. In fact, more people die of lung cancer than of colon, breast, and prostate cancers combined. Although lung cancer is largely induced by smoking, there is strong evidence for genetic susceptibility and gene-environment interactions in the development of lung cancer. Inbred mouse models offer an effective means of identifying candidate lung cancer susceptibility loci since genetic heterogeneity and enormous variation in exposure levels to environmental agents make it difficult to identify lung cancer susceptibility loci in humans. Papg-1 (pulmonary adenoma progression 1) was previously mapped to a region on mouse chromosome 4. This locus contains a candidate gene, Cdkn2a also referred to as Ink4a/Arf, which dually encodes two established tumor suppressors p16
Introduction
Although there have been no reports on localization and identification of human lung cancer susceptibility genes, there is evidence from segregation analyses that susceptibility of the human population to lung cancer follows a pattern of autosomal dominant Mendelian inheritance (Sellers et al., 1990 (Sellers et al., , 1992 . Spontaneous aberrations of human chromosome 9 (where the Cdkn2a gene is located) in peripheral blood lymphocytes were found to be a marker for familial lung carcinoma (Wu et al., 1997) . Subsequently, a germline p16
INK4a mutation was detected in a melanoma kindred that has a history of aggregation of nonsmall-cell lung carcinomas (Yarbrough et al., 1996) . These results suggest that germline p16
INK4a mutations may predispose to lung cancer in some families.
The Cdkn2a locus encodes two functionally distinct tumor suppressors, p16
INK4a and ARF (Kamb et al., 1994; Quelle et al., 1995) . p16
INK4a controls cell cycle transition by inhibiting the D-type cyclin-dependent kinases (CDK4 & CDK6) which regulate the phosphorylation of Rb (Serrano et al., 1993) . In its hypophosphorylated state, Rb maintains a G1-phase block by sequestration of E2F transcription factors (Weinberg, 1995) . ARF is encoded by the Cdkn2a gene in which an alternative first exon is spliced into exon 2 in a reading frame different from that of p16 INK4a (Pomerantz et al., 1998; Stone et al., 1995) . p16 INK4a and ARF are immunologically and functionally distinct proteins (Stone et al., 1995) . For example, ARF does not directly interact with the CDKs but rather binds MDM2 and blocks MDM2-induced degradation of p53 (Pomerantz et al., 1998; Zhang et al., 1998b) . This process may be mediated by ARF through relocalization of MDM2 from the cell nucleus to the nucleolus and the induction of p53 and p21 (Tao and Levine, 1999; Weber et al., 1999) . ARF acts upstream of p53 in the abovementioned cellular pathway and negatively regulates the effects of specific stresses including aberrant cell cycle entry in Rb deficient cells, oncogenic signaling, DNA damage, and microtubule disruption (Kamijo et al., 1998; Khan et al., 2000; Levine, 1997; Pomerantz et al., 1998; Prives, 1998; Sherr, 1998; Stone et al., 1995; Stott et al., 1998; Tao and Levine, 1999; Weber et al., 1999; Zhang et al., 1998b) . Thus, the Cdkn2a locus encodes two proteins that regulate two very important tumor suppressor pathways, RB and p53.
Evidence of the candidacy of the Cdkn2a as a lung tumor susceptibility gene has resulted from studies in mice . The mouse lung system affords an ideal model for the study and validation of the mechanisms underlying tumor susceptibility and development since strain differences in tumor susceptibility are analogous to those encountered among human populations (Ponder, 1990) . Different inbred mouse strains show widely different susceptibilities to both spontaneously occurring and chemically induced lung tumors, thus enabling genetic linkage analysis of tumor susceptibility genes (Andervont, 1938; Malkinson, 1989; Shimkin, 1955) . A locus on mouse chromosome 4 (encompassing the Cdkn2a gene) showing a strong linkage to lung tumor susceptibility was mapped using an F 2 cross between the A/J and BALB/cJ strains of mice (Festing et al., 1998) . This locus has a maximum LOD score of 6.4 in which the susceptible allele occurred in BALB/cJ mice (Festing et al., 1998) . The same locus was found to be associated with lung tumor progression in (BALB/cJxSWR/J)F 2 mice with a LOD score of 11 in which the susceptible allele again donated by the BALB/ cJ strain (Manenti et al., 1997) . Because this locus is more significantly associated with lung tumor size, it was named the 'pulmonary adenoma progression 1 (Papg-1)' locus (Manenti et al., 1997) . As shown in Figure 1a , both studies indicate a linkage to chromosome 4 with the strongest at or near the Cdkn2a gene (Festing et al., 1998; Manenti et al., 1997) .
DNAs from A/J and BALB/cJ mice were sequenced for sequence variation in the mouse Cdkn2a gene . As shown in Figure 1b , two variants of the gene were distributed between the 29 strains evaluated. The sequence polymorphisms observed constituted an amino acid difference at positions 18 and 51. Most strains possessed histidine and valine at these locations, except for six strains (BALB/cJ, O20, C3H/HeJ, C3H/2IBG, CBA/J, and PL/J), which possessed proline and isoleucine. Functional analysis showed that the proline 18/ isoleucine 51 p16
INK4a variant was diminished in NIH3T3 fibroblast growth suppression, CDK6 binding, and CDK6 inhibition compared with the histidine 18/valine 51 variant (Herzog et al., 1999) . The substitution at position 51 of Cdkn2a is within exon 2 and produces a arginine to histidine substitution of ARF in the group of mice including BALB/cJ . This change, however, had no effect on ARF function (Herzog et al., 1999) . These results are consistent with the hypothesis that strain-specific variation in p16 INK4a function, but not in ARF function, may play an important role in lung cancer predisposition and development.
Results
In the present study, a mouse lung tumor bioassay was conducted to determine whether heterozygous Cdkn2a gene deficient mice carrying the A/J allele would be more susceptible to lung tumor progression than heterozygous Cdkn2a gene deficient mice carrying the BALB/cJ allele. As shown in Figure 2a , 7-week-old (BALB/cJxN5A/J Cdkn2a +/7 ) F 1 mice (wild type and heterozygous Cdkn2a knockout) and N5A/J Cdkn2a +/7 mice (wild type and heterozygous Cdnk2a knockout) were given a single dose of urethane (1 mg/g body weight). As shown in Figure 2b , heterozygous Cdkn2a knockouts exhibited a striking enhancement in tumor progression in both (BALB/ cJxN5A/J Cdkn2a +/7 ) F 1 mice and N5A/J Cdkn2a
mice when compared to their wild type littermates 9 months after urethane treatment. More interestingly, differential effects on tumor progression were seen between the presence of a BALB/cJ allele and the presence of an A/J allele. As shown in Figure 2b , there was an approximate sixfold increase in tumor size in . Amino acid changes that distinguish Cdkn2a of BALB/cJ mice vs A/J mice are boxed p16
INK4a is a candidate for the Papg1 locus Z Zhang et al the heterozygous Cdkn2a deficient mice carrying a BALB/cJ allele and a ninefold increase in tumor size in the heterozygous Cdkn2a deficient mice carrying an A/ J allele (P50.001). The remaining BALB/cJ or A/J allele of the Cdkn2a gene was lost in all resulting lung adenocarcinomas examined from the respective heterozygous Cdkn2a deficient mice (Figure 3 ). This observation indicates that the A/J allele of the Cdkn2a gene is a more potent tumor suppressor than the BALB/cJ allele. Histologically, 10% of the lung tumors from the wild type mice were lung adenocarcinomas, whereas *60% of the lung tumors from the heterozygous Cdkn2a-deficient A/J mice carrying an A/J allele and *30% of the lung tumors from (BALB/ cJxA/J)F 1 mice carrying a BALB/cJ allele were adenocarcinomas (Figure 4a -d ; P50.001).
As shown in Figure 3 , LOH of the Cdkn2a alleles in lung adenocarcinomas from (BALB/cJxN5A/J Cdkn2a +/7 ) F 1 (BALB/cJxN5A/J Cdkn2a +/+ ) F 1 , and N5A/J Cdkn2a +/7 mice were determined. Allelic losses at D6MIT14, which is approximately 34 kb distal to Cdkn2a, were detected in 10 out of 10 adenocarcinomas from (BALB/cJxN5A/J Cdkn2a +/7 ) F 1 and 10 out of 10 adenocarcinomas from (BALB/ cJxN5A/J Cdkn2a +/+ ) F 1 mice (Figure 3 ). Interestingly, LOH of the BALB/cJ allele was observed in tumors from (BALB/cJxN5A/J Cdkn2a +/7 ) F 1 mice when gene targeting disrupted the A/J allele, while the A/J allele was lost in tumors from (BALB/cJxN5A/J Cdkn2a +/+ ) F 1 mice. After five generations of backcrossing, all loci surrounding the Cdkn2a locus tested are homozygous for A/J alleles. Therefore, LOH status in tumors from N5A/J Cdkn2a +/+ mice could not be determined. However, we were successful in assessing LOH of the Cdkn2a alleles in tumors from N5A/J Cdkn2a +/7 mice using the neo cassette in the targeted region as a marker (Figure 3c) . Again, LOH of the remaining A/J allele was lost 10 out of 10 lung adenocarcinomas from N5A/J Cdkn2a +/7 mice. These results suggest that allelic loss of the Cdkn2a alleles contribute to lung tumor progression and the loss of the A/J allele of the p16
INK4a gene apparently contributes more significantly than the loss of the BALB/cJ allele to the tumor progression process.
There is no significant increase in tumor multiplicity in heterozygous Cdkn2a deficient mice when compared to their wild type littermates. As shown in Figure 2c , 100% of treated mice had lung tumors 9 months after ) F 1 mice (wild type and heterozygous Cdkn2a knockout) and N5A/J Cdkn2a +/7 mice (wild type and heterozygous Cdkn2a knockout) were given a single dose of urethane (1 mg/g body weight) and 9 months later, animals from all five groups were euthanized by CO 2 asphyxiation. For each mouse, lung tumors were counted, sized, and subjected to histopathology; (b) Lung tumor size in urethane-treated mice; (c) Lung tumor multiplicity in urethane-treated mice. +/7 ) mice carrying the A/J allele with urethane induced an average of 41.2 tumors/mouse (n=33), and treatment of wild type littermates induced an average 40.6 tumors/mouse (n=26). In contrast to the observed differences in tumor sizes between mice carrying the BALB/cJ allele and carrying the A/J allele, there is no significant difference in tumor multiplicity between the heterozygous Cdkn2a deficient mice carrying either allele compared to their wild type counterparts. These results suggest that the Cdkn2a allele is the major contributor to the observed differences in tumor size difference; therefore, this gene is a strong candidate for Papg1.
Discussion
Our data provide sufficient evidence to support the candidacy of the Cdkn2a gene for the Papg1 locus. First, the Cdkn2a gene maps to the same region that contains Papg1 and displays 100% concordance between allele type and tumor susceptibility (Festing et al., 1998; Manenti et al., 1997) . Genetic evidence that Papg1 is a tumor progression gene is primarily based on mapping studies using (BALB/cJxSWR/J)F 2 mice (Manenti et al., 1997) . Lung tumors found in (BALB/cJxSWR/J)F 2 mice carrying the SWR allele of the Cdkn2a gene were very small with an average diameter of less than 0.6 mm (0.6+0.1 mm) (Festing et al., 1998) . While this locus was found to be associated with tumor multiplicity in (BALB/cJxA/J)F 2 mice, the effect on tumor size was not examined (Festing et al., 1998) . However, the observation of tumor number difference reflects difference in tumor size since only those tumors with a diameter larger than 1 mm were enumerated which eliminated most of the tumors found in (BALB/cJxA/J)F 2 mice carrying the A/J allele of the Cdkn2a gene (Festing et al., 1998) . This could similarly explain the results from a recent report showing an approximate fourfold increase in tumor multiplicity in p16
INK4a7/7 mice and nearly twofold increase in tumor multiplicity in p16
INK4a+/7 mice when compared with that of p16
INK4a+/+ mice where smaller tumors were not fully represented (Sharpless et al., 2001) . Although a trend toward increased lung tumor size was observed in the p16
INK4a7/7 and p16
INK4a+/7 mice, it was not possible to evaluate the effect of p16
INK4a deficiency on tumor progression because the mice were terminated before any significant tumor progression could occur (only 3 months after urethane treatment) (Sharpless et al., 2001) . In fact, we examined four mice from each genotypic group ((BALB/cJxN5A/J Cdkn2a +/7 ) F 1 and N5A/J Cdkn2a +/7 mice) 4 months after treatment with urethane and found no significant difference in tumor size or multiplicity between mice with heterozygous INK4a is a candidate for the Papg1 locus Z Zhang et al Cdkn2a deficiency and their wild type littermates (data not shown). Furthermore, no LOH of the Cdkn2a alleles was observed in any of the tumors examined (data not shown). Based on our past experience, we observed, at least in this study, that the differences in tumor multiplicity are, in a significant degree, reflecting differences in tumor size and that only the large tumors were being counted while the smaller tumors are not observed. And this could be true for most of the studies on the genetics of tumor susceptibility suggesting that the timing of sacrifice (latency) is an important factor in determining differences in progression.
Second, there are sequence variations in the Cdkn2a gene resulting in amino acid differences among mouse strains, with two variants of the gene distributed between the 29 strains of mice which segregate with the observed differences in tumor size (Herzog et al., 1999; . Third, functional analysis showed that the proline 18/isoleucine 51 p16
INK4a variant was diminished in NIH3T3 fibroblast growth suppression, CDK6 binding, and CDK6 inhibition compared with the histidine 18/valine 51 variant and its segregates with susceptibility to lung tumor progression (Herzog et al., 1999) . In contrast, both of the ARF variants suppressed growth with similar potencies suggesting no role for this variation in this particular tumor phenotype (Herzog et al., 1999) .
Fourth, we have observed LOH of the Papg1 region exclusively in lung adenocarcinomas of intervariant F 1 hybrids (Herzog et al., 1994; . LOH of this region showed significant bias for the loss of the allelic form coding for histidine at codon 18 regardless of the gender of the donor parent . For example, this allele was lost in 100% of (BALB/cJxDBA/2J)F 1 , 84% of (C3H/HeJxA/ J) F 1 , 82% of (C57BL/6JxC3H/HeJ) F 1 , 72% of the (A/JxC3H/HeJ) F 1 , and 100% of (BALB/cJxN5A/J Cdkn2a +/+ ) F 1 lung tumors (biased allele lost is underlined) . These results suggest that the allelic form coding for proline at codon 18 is weaker in growth suppression than the allelic form coding for histidine at codon 18 and this difference is exploited during tumor progression. Hence, the allele that encodes a more potent growth suppressor is selected for allelic loss during lung tumor progression in intervariant hybrids.
Finally, the results from the present study demonstrate that mice that lost one copy of the A/J allele of the Cdkn2a gene displayed significantly larger lung tumors than those that lost one copy of the BALB/cJ allele of the Cdkn2a gene. Our in vivo carcinogenesis studies offer conclusive results that Cdkn2a is a lung tumor progression gene for the Papg1 locus. Specifically, p16 INK4a allele of the Cdkn2a gene is the candidate for Papg1. The P18/I51 p16
INK4a variant from the BALB/cJ mouse consisting of changes in P18?H18 and I51?V51 when compared to that of the A/J mouse. H18 variant of the p16
INK4a gene exhibited 0%, V51 variant 25%, and the combination of H18 & V51 0% of the activity in inhibiting Rb phosphorylation when compared to that of the A/J allele (Zhang et al., 1998a) . These results indicate that both of these two specific amino acid changes in p16
INK4a variants are likely to be responsible for the observed growth suppression effect.
Our observation that strain-specific variation in p16
INK4a function, but not in ARF function, may play an important role in lung cancer predisposition and development is consistent with a recent study that implicated the Cdkn2a locus as a primary candidate for the mouse plasmacytoma susceptibility locus (or Pctr1) (Zhang et al., 1998a; . Pctr1 was recently mapped to a 1.5-centimorgan (cM) chromosomal region that included Cdkn2a (Zhang et al., 2001) . Allelic variants of p16
INK4a found between BALB/cJ and DBA/2 mice were tested for their ability to inhibit the activity of cyclin D2/CDK4 (Zhang et al., 1998a) . The BALB/cJ allele of p16
INK4a was found to be defective and, thus, a strong candidate for the Pctr1 gene (Zhang et al., 1998a) . Two ARF alleles found between BALB/cJ and DBA/2 mice displayed similar potencies in these assays (Zhang et al., 2001) . It is highly likely that Cdkn2a is both a candidate for the Papg1 locus for lung tumor progression and for the Pctr1 locus for plasmacytoma development in mice. Based upon in vitro results, ARF variants are unlikely to contribute significantly to these effects, although the ARF haploinsufficient state in this study may further enhance the impact of p16
INK4a allelic variation. In summary, our data provide the first functional evidence in vivo of naturally occurring variation of p16
INK4a contributing to differential lung tumor progression in mice. Mouse lung tumor progression (from adenoma to adenocarcinoma) is the most important step of lung carcinogenesis since metastasis is extremely rare in mice. The identification of Cdkn2a as a candidate gene for the Papg1 locus has important implications in human lung cancer. Recently, Yarbrough et al. (1996) reported a p16
INK4a germline mutation in a family with four cases of early-onset lung cancer in association with melanoma, as well as oral and prostate cancers in melanoma-affected individuals. This observation, together with results from the present study, strongly indicate that carriers of defective p16
INK4a predisposed to familial lung cancer, especially in those lung cancer kindreds with early onset melanoma or pancreatic cancer. Thus, the identification of Cdkn2a as a candidate for lung cancer susceptibility can be directly applied to the identification of individuals at risk for familial lung cancer, and for developing appropriate preventive or therapeutic measures.
Materials and methods

Reagents
Urethane (499% pure) was purchased from Sigma Chemical Co. (St. Louis, MO, USA) which was dissolved phosphatebuffered saline immediately before use in bioassays.
Animals and generation of F 1 heterozygotes
The development of the Cdkn2a 7/7 mice (knockout mice lacking both p16
INK4a and p19 ARF genes) was reported previously (Serrano et al., 1996) . Cdkn2a 7/7 mice (on 
